Keyphrases
Metastatic Melanoma
76%
Immune Checkpoint Inhibitors
73%
Real Patients
64%
Melanoma
61%
Adjuvant Immunotherapy
58%
Ipilimumab
58%
Nivolumab
58%
Checkpoint Inhibitors
50%
Confidence Interval
40%
Checkpoint Inhibitor Colitis
38%
Stage III-IV
35%
Anti-PD-1
29%
IL-6 Blockade
29%
Bcl-xL
29%
Tocilizumab
29%
Arthritis
29%
Tumor-infiltrating Lymphocytes
29%
Tumor-infiltrating Lymphocyte Therapy
29%
Advanced Melanoma
29%
Large B-cell Lymphoma
29%
Gastroenteritis
29%
Locally Advanced Prostate Cancer
29%
Hepatotoxicity
29%
Risk Factors
29%
Tofacitinib
29%
Hepatitis
29%
Medical Management
29%
Fecal Microbiota Transplantation
29%
First-in-man Study
29%
Immune-related
29%
Health-related Quality of Life
29%
Arginase-1 (Arg-1)
29%
Indoleamine 2,3-dioxygenase 1 (IDO1)
29%
Immune Modulatory Vaccine
29%
Metastatic Tumor
29%
Mental Health
29%
Quality of Life
29%
Programmed Death
29%
Targeting Peptide
29%
Peptide Vaccine
29%
Phase I Trial
29%
Vaccination
28%
Monotherapy
27%
Diarrhea
21%
Immune-related Adverse Events
21%
Enteritis
19%
Common Terminology Criteria for Adverse Events (CTCAE)
19%
Autoimmune Hepatitis
16%
Colitis
15%
Infliximab
15%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Melanoma
87%
Metastatic Melanoma
79%
Nivolumab
64%
Immunotherapy
58%
Neoplasm
53%
Ipilimumab
47%
Colitis
43%
Adverse Event
43%
Vaccination Policy
41%
Clinical Study
32%
Glucocorticoid
32%
Prostate Cancer
29%
Feces microflora
29%
Tocilizumab
29%
Arginase 1
29%
Indoleamine 2,3 Dioxygenase
29%
Arthritis
29%
Hepatotoxicity
29%
B Cell Lymphoma
29%
Tofacitinib
29%
Enterocolitis
29%
Solid Malignant Neoplasm
29%
Peptide Vaccine
29%
Phase I Trials
29%
Immunosuppressive Agent
28%
Monotherapy
24%
CD8 Antigen
24%
Malignant Neoplasm
22%
Recurrent Disease
20%
Comorbidity
19%
Diarrhea
15%
Antibiotics
14%
Infection
14%
Enteritis
14%
Immunogenicity
14%
Progression Free Survival
13%
Infliximab
11%
Disease
9%
Adjuvant
9%
Preclinical Study
9%
Intraperitoneal Injection
9%
Cross Sectional Study
9%
Elimination
8%
Overall Survival
8%
Remission
8%
Cytokine
7%
Aspartate Aminotransferase
7%
Combination Therapy
7%
Vedolizumab
7%
Medicine and Dentistry
Immune Checkpoint Inhibitor
92%
Metastatic Melanoma
68%
Nodular Melanoma
58%
Colitis
43%
Nivolumab
42%
Ipilimumab
33%
Clinical Study
32%
Glucocorticoid
32%
T Cell
32%
Indoleamine 2,3 Dioxygenase
29%
Arginase 1
29%
Interleukin-6
29%
Peptide Vaccine
29%
Fecal Microbiota Transplantation
29%
Tumor Infiltrating Lymphocyte
29%
Mental Health
29%
Tofacitinib
29%
Liver Toxicity
29%
Quality of Life
29%
Solid Malignant Neoplasm
29%
Tocilizumab
29%
Immunotherapy
29%
Enterocolitis
29%
Arthritis
29%
Phase I Trials
29%
Adverse Event
18%
Monotherapy
17%
Diarrhea
15%
Immune-Related Adverse Events
15%
Enteritis
14%
Antibiotic Therapy
14%
Immunosuppressant
14%
Infection
14%
Progression Free Survival
13%
Immunosuppressive Drug
13%
Neoplasm
13%
Malignant Neoplasm
12%
Infliximab
11%
Disease
9%
T-Helper Cell
9%
Cytotoxic T-Cell
9%
Immunogenicity
9%
Overall Survival
8%
Peripheral Blood Mononuclear Cell
7%
Aspartate Aminotransferase
7%
Tumor Microenvironment
7%
Combination Therapy
7%
Steroid Treatment
7%
Vedolizumab
7%
Liver Enzyme
7%